Rosuvastatin & Ezetimibe, a USFDA approved lipid lowering agent which possesses superior efficacy in reducing LDL-C as well as achieving the target LDL-C goal in ASCVD patients with less Drug Discontinuation rates due to adverse effects of high dose statin monotherapy. Ruvan-Z is indicated as an adjunct to diet in patients with primary hyperlipidemia and, where appropriate, as an adjunct to other LDL-C-lowering therapies in patients requiring additional LDL-C reduction. With this introduction, Aristopharma Ltd. aims to provide healthcare professionals with an effective combination option to support comprehensive lipid management and help patients achieve their LDL-C goals.
FR
DE